Fully integrated ophthalmic platform
From laboratory to market
Founded in 2017, Zhaoke Ophthalmology (SEHK: 6622) is a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs in the world. The company was listed in the Main Board of the Hong Kong Stock Exchange on 29 April 2021.
Zhaoke Ophthalmology has a comprehensive drug portfolio of innovative and generic treatments covering six major eye diseases across both the front and back of the eye. Many of the drugs are being produced in its state-of-the-art and fully functional development and production facility in Nansha, Guangzhou.
Zhaoke Ophthalmology is focusing on advancing towards the goal of product commercialisation, and achieve the objective of improving visual health in China through scientific research as soon as possible.
Through its ambitious growth strategy, including partnering with domestic and international pharmaceutical companies, Zhaoke Ophthalmology’s goal is to become a leader in ophthalmology in the world.
Innovative + generic drugs
Comprehensive pipeline
In designing our pipeline, we have initially placed strategic emphasis on five major ophthalmic indications in China in terms of market potential, including dry eye disease, or DED, wet age-related macular degeneration, or wAMD, diabetic macular edema, or DME, myopia and glaucoma. Through this pipeline strategy, we aim to become the essential one-stop solution.
We have developed internal capabilities in key aspects of ophthalmic drug development. Our specialized in-house research, development, clinical and regulatory capabilities have enabled us to concurrently advance multiple innovative and generic drug candidates through the preclinical and clinical phases. We have a solid track record in business development, having in-licensed a number of drug candidates across major indications with high growth potential from international partners. Setting us apart from competitors in China, we have established a commercial-scale advanced manufacturing facility, which is designed and built for ophthalmic drugs in compliance with cGMP requirements of China, the United States and the European Union. We are also assembling a commercial team with extensive experience covering various nationwide sales channels and ophthalmologists in China. We believe these established capabilities will help us bring innovative and comprehensive ophthalmic therapies to market, and become the partner of choice of multinational pharmaceutical companies.
?
